Cerevu
1 known investors
CereVu develops a non-invasive pain assessment system that uses near-infrared spectroscopy and a wearable sensor array to derive objective pain indices from cerebral oxygenation changes, along with heart rate, respiratory rate, and SpO₂. Its AI-derived biomarkers target clinical settings such as emergency departments and pain management, and the technology has been validated in studies with institutions including Stanford University.
AI & Machine LearningDigital HealthMedical Devices